Veracyte (VCYT) Revenue (2012 - 2026)

Veracyte has reported Revenue for 15 years, with the latest figure at $150.3 million in Q2 2026.

• Revenue for Q2 2026 came in at $150.3 million, up 15.49% year-over-year; the trailing twelve-month figure through Jun 2026 was $561.9 million (up 17.28% YoY), and the FY2025 annual result was $517.1 million, up 16.01% from the prior year.
• Revenue advanced to $150.3 million in Q2 2026, from $139.1 million in the prior quarter.
• Over five years, Revenue peaked at $150.3 million in Q2 2026 and troughed at $67.8 million in Q1 2022.
• A 5-year average of $106.1 million and a median of $106.3 million in 2023 frame the typical range for Revenue.
• The widest annual swing landed in 2022, when Revenue surged 84.68%; it then gained 13.75% in 2025.
• A 5-year view of Revenue shows it stood at $80.3 million in 2022, then rose by 22.29% to $98.2 million in 2023, then advanced by 20.81% to $118.6 million in 2024, then increased by 18.55% to $140.6 million in 2025, then increased by 6.89% to $150.3 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $150.3 million in Q2 2026, $139.1 million in Q1 2026, and $140.6 million in Q4 2025.